Status:
COMPLETED
ASPIRIN: Neurodevelopmental Follow-up Trial
Lead Sponsor:
NICHD Global Network for Women's and Children's Health
Collaborating Sponsors:
Thomas Jefferson University
RTI International
Conditions:
Neurodevelopmental Abnormality
Eligibility:
All Genders
33-39 years
Brief Summary
A total of 620 children will be enrolled in this study from six sites in sub-Saharan Africa, South Asia, and Latin America. Half of the children's mothers will have taken aspirin and half will have ta...
Detailed Description
An estimated 250 million children under the age of 511 worldwide are at risk for not achieving their developmental potential; 52.9 million children under five years of age in low- and middle-income co...
Eligibility Criteria
Inclusion
- Mother was enrolled in the GN ASPIRIN trial
- Mother consented to be recontacted
- Child's parents or guardians are willing and able to give consent
- Child is between 33-39 months of age
- Child does not have significant congenital anomaly (blind or deaf) that would affect them from completing study assessments
- Child does not have other medical conditions that would preclude the child from completing study assessments.
Exclusion
- The child does not meet the inclusion criteria.
Key Trial Info
Start Date :
September 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 15 2022
Estimated Enrollment :
666 Patients enrolled
Trial Details
Trial ID
NCT04888377
Start Date
September 1 2021
End Date
June 15 2022
Last Update
October 21 2024
Active Locations (14)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alabama, Birmingham
Birmingham, Alabama, United States, 35233
2
University of Colorado Health Sciences Center
Denver, Colorado, United States, 80208
3
Christiana Care
Newark, Delaware, United States, 19718
4
Boston University
Boston, Massachusetts, United States, 02115